Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omicron-containing COVID-19 vaccine (Catholic Kwandong University) refers to the specific Omicron-variant-targeting COVID-19 vaccine used as an intervention in a Phase 4 clinical trial (NCT06081374) conducted by Catholic Kwandong University. This vaccine is the formulation approved for the 2023-2024 season, which typically consists of monovalent mRNA or protein subunit vaccines targeting the SARS-CoV-2 XBB.1.5 subvariant. The study evaluates the immunogenicity and safety of this booster, particularly when co-administered with a quadrivalent influenza vaccine, by analyzing B-cell and T-cell responses in healthy adults.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Omicron-containing COVID-19 vaccine (Catholic Kwandong University).